Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2985 - ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A phase II study of the Spanish TTD Group

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Colon and Rectal Cancer

Presenters

Ramon Salazar

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

R. Salazar1, D. Azuara1, J.M. Viéitez2, D. Paez3, C. Santos1, E. Falcó4, E. Elez5, C. López López6, M. Valladares-Ayerbes7, L. Robles8, P. Garcia-Alfonso9, C. Buges10, G. Duran Ogaya11, M.A. Salud Salvia12, V. Navarro1, G. CAPELLA1, E. Aranda Aguilar13

Author affiliations

  • 1 Translational Research Laboratory And Department Of Medical Oncology,, Institut Català d'Oncologia-IDIBELL, 08907 - Barcelona/ES
  • 2 Medical Oncology, Hospital Universitario Central de Asturias, 33011 - Oviedo/ES
  • 3 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 4 Medical Oncology, Hospital Son Llatzer, Palma de Mallorca/ES
  • 5 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander/ES
  • 7 Medical Oncology, Hospital Universitario a Coruña, 15006 - A Coruña/ES
  • 8 Medical Oncology, Hospital 12 de Octubre, Madrid/ES
  • 9 Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid/ES
  • 10 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 11 Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, 29010 - Malaga/ES
  • 12 Medical Oncology, Hospital de Lleida Arnau de Vilanova, Lérida/ES
  • 13 Medical Oncology, University Hospital Reina Sofia. CIBERONC Instituto de Salud Carlos III, 14004 - Cordoba/ES
More

Resources

Abstract 2985

Background

In metastatic colorectal cancer (mCRC) recent studies have shown the importance to accurately quantify low-abundance mutations of RAS pathway because response to anti-EGFR therapy may depend on certain mutation thresholds. We designed a clinical trial to compare clinical outcomes of patients selected with different analytical sensitivity thresholds for RAS/BRAF mutated alleles using a highly sensitive and quantitative technique of digital PCR (dPCR).

Methods

Hotspots including RAS (KRAS and NRAS exons 2/3/4) and BRAF (exon 15) were prospectively analyzed in tumour FFPE samples from 61 patients with mCRC included in the ULTRA trial. Patients had received one or two previous chemotherapy lines and were deemed resistant to irinotecan. Response rate (RR), progression-free survival (PFS) and overall survival (OS) were correlated with the mutational status based on three different cut-off points (0.1%, 1% and 5%).

Results

The overall RR was 51.7% and comparative analysis of clinical outcomes translated into a differential progression free survival (PFS), response rate (RR) and progression disease (PD) in the different cohorts defined by the 3 selected analytical sensitivity cut-off points (Table). PFS prediction was higher when we considered a threshold of 5% in RAS/BRAF scenario (HR mut vs wt = 3.85; CI95% [1.16-12.82], p = 0.018).

Conclusions

Optimal sensitivity RAS/BRAF mutational analysis cut-off for clinical outcome prediction lies between 1 and 5% (closer to 5%). Increasing analytical sensitivity worsens patient’s selection. Further sensitivity threshold comparative analysis will define an optimal cut-off.Table:

547P

Highly-sensitive digital PCR
cut-off 0.1%cut-off 1%cut-off 5%
RAS + BRAFmut/wt (n/n)14/478/533/58
RR % (mut/wt)46.2/52.137.5/52.833.3/51.7
SD % (mut/wt)46.2/33.350.0/34.033.3/36.2
PD % (mut/wt)7.7/12.512.5/11.333.3/10.3
PFS monthsmedian (mut/wt)9.3/7.67.4/7.64.0/8.8
HR (mut vs wt)0.820.773.85
HR (95%CI)0.43-1.560.35-1.691.16-12.82
P-value0.5000.5100.018
OS monthsmedian (mut/wt)17.4/12.526,22/13.8816.05/16.18
HR (mut vs wt)0.5520.5421.57
HR (95%CI)0.24-1.250.19-1.540.48-5.11
P-value0.1530.2500.46

Clinical trial identification

NCT01704703

Legal entity responsible for the study

Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

Funding

Public funding from the Spanish Ministry of Health, Social Policy and Equality. (Trial Ref: EC11-050)

Disclosure

J.M. Viéitez: Consultant or advisory relationship and research funding: Amgen. M. Valladares-Ayerbes: Consultant or advisory relationship and honoraria: Roche, Amgen, Merck Serono. E. Aranda Aguilar: Honoraria for advisory role from Amgen, Bayer, Celgene, Merck, Roche, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.